Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.44 |
| ▸ | UTS2R | Q9UKP6 | 5/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.43 |
| ▸ | SLC5A7 | Q9GZV3 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CCR3 | P51677 | 2/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12437859 | 0.94 | TP53 (0.47) | SLC2A1UTS2ROPRK1MEN1KMT2A | |
| SCHEMBL12437847 | 0.94 | TP53 (0.48) | UTS2ROPRK1TP53CCR3HRH1 | |
| SCHEMBL12437906 | 0.89 | OPRK1 (0.41) | SLC2A1UTS2ROPRK1SLC5A7MEN1 | |
| SCHEMBL12437883 | 0.84 | OPRK1 (0.45) | SLC2A1UTS2ROPRK1SLC5A7MEN1 | |
| SCHEMBL12437944 | 0.84 | KMT2A (0.47) | UTS2ROPRK1SLC5A7MEN1KMT2A | |
| SCHEMBL12437734 | 0.83 | HRH1 (0.46) | SLC2A1UTS2ROPRK1SLC5A7MEN1 | |
| SCHEMBL12437745 | 0.83 | UTS2R (0.59) | SLC2A1UTS2RMEN1KMT2AEPHX2 | |
| SCHEMBL12437952 | 0.83 | MEN1 (0.46) | UTS2ROPRK1MEN1KMT2AEPHX2 | |
| SCHEMBL12437763 | 0.83 | UTS2R (0.51) | SLC2A1UTS2ROPRK1SLC5A7MEN1 | |
| SCHEMBL12437948 | 0.81 | SLC5A7 (0.56) | UTS2ROPRK1SLC5A7MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | AVALON PHARMACEUTICALS | 2011-07-21 | — | — | US | disclosed |
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | AVALON PHARMACEUTICALS | 2011-07-21 | — | — | US | disclosed |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | AVALON PHARMACEUTICALS | 2009-02-05 | — | — | US | disclosed |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | AVALON PHARMACEUTICALS | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | HPGDS, HPGD, DPYD | SLC2A1 3508/4885UTS2R 854/4885OPRK1 980/4885 |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | HPGDS, HPGD, DPYD | SLC2A1 3508/4885UTS2R 854/4885OPRK1 980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.